Why do I feel nothing with CBD? Six avenues to explore

This is the first hypothesis to check. According to the DGCCRF, a significant share of the CBD products inspected were non-compliant: misleading labelling, a CBD content lower than stated, the presence of banned cannabinoids. Ask for the batch's certificate of analysis (CoA) from an independent laboratory, check the actual CBD content against the label, and make sure there is no HHC, H4CBD, THCP or HHCO, classified as narcotics by the ANSM since 2023-2024. Without a CoA, you do not really know what you are consuming.

Not all routes share the same kinetics or the same bioavailability. According to Millar et al. (2018): the sublingual route offers an estimated bioavailability of 13-19% with a Tmax of 15-45 minutes; the oral route is lower (6-15%) with a hepatic first-pass effect; vaporisation has a higher bioavailability but a shorter duration; topical use remains a local skin effect with no notable systemic absorption. If you swallow your sublingual oil without holding it under your tongue, most of the CBD goes through the liver and is eliminated.

No French authority has set a dose for wellness CBD. On 9 February 2026 the EFSA published a provisionally safe daily dose of 0.0275 mg/kg/day (≈ 2 mg/day for 70 kg) for ingested CBD. There are two opposite pitfalls: a dose that is too low — one or two drops of a weakly concentrated oil may represent only a few milligrams; and a dose that is too high, which can cause tiredness or discomfort that clouds what you feel. The usual approach is to start low (5-10 mg per intake) and adjust slowly. Our dosage benchmark sets out this progression.

A product tested for two or three days does not allow any conclusion. Several brands recommend an evaluation window of four to six weeks at a stable dose and time of day — a practical benchmark, not an official standard. During that period: same product, same dose, same time slot, a brief log of what you feel, and limited external variables (alcohol, late screens, changes of routine). Our article on how long to wait before assessing what you feel sets out this method.

Many people expect a "visible" or "strong" effect from CBD, fed by marketing content that goes beyond what French law permits anyone to claim. The MILDECA points out that no therapeutic claim is validated for wellness CBD. Reasonable expectations: an enjoyable routine to fit into your day, a possible subjective sense of relaxation, with no guarantee. Unrealistic expectations: curing chronic pain, treating diagnosed insomnia, replacing an anxiolytic, obtaining a "high".

Several documented factors can alter what you feel: metabolism (CYP3A4, CYP2C19), which varies from person to person, body mass and fat composition, food intake (a meal rich in fats increases oral bioavailability), concomitant medicines, tiredness, stress and sleep. ANSES also advises against CBD for pregnant and breastfeeding women and for minors, and urges caution in people on medical treatment.

Three legitimate options: change the product (another concentration, another cannabinoid profile, another format), change the route of administration, or conclude that CBD brings you nothing. CBD is not a medicine and is not suited to everyone.

Does CBD always end up working if you persist?

No. No French authority guarantees any effect. "Persisting" only makes sense within a reasonable evaluation period of 4 to 6 weeks at a stable dose; beyond that, with neither an effect nor any discomfort, it is legitimate to conclude that this product does not suit you.

Could my oil be too dilute?

Possibly. Check the concentration in mg/mL on the label and the equivalent dose in mg per drop. A 5% oil in a 10 mL bottle represents 500 mg of CBD in total, or roughly 2.5 mg per drop.

Should CBD be taken on an empty stomach to feel it better?

Taking it with a meal rich in fats increases oral bioavailability according to international pharmacokinetic data. The sublingual route is less sensitive to this effect.

Will a "full spectrum" product be felt more than an isolate?

Some hypotheses suggest a complementary role for minor cannabinoids and terpenes, known as the "entourage effect". Clinical data remain limited: this is something to judge individually.